Genmab A/S (NASDAQ:GMAB) Cut to Hold at Wall Street Zen

Genmab A/S (NASDAQ:GMAB - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Sunday.

Several other research firms also recently commented on GMAB. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Truist Financial increased their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.13 on Friday, hitting $21.88. 837,917 shares of the stock traded hands, compared to its average volume of 1,249,735. The company has a market capitalization of $14.04 billion, a PE ratio of 12.43, a P/E/G ratio of 6.65 and a beta of 0.94. The business has a 50 day simple moving average of $21.18 and a 200 day simple moving average of $20.78. Genmab A/S has a one year low of $17.24 and a one year high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The company had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. On average, equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of GMAB. Bank of New York Mellon Corp grew its position in Genmab A/S by 4.0% during the 4th quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock worth $1,495,000 after purchasing an additional 2,749 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Genmab A/S by 134.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,177 shares of the company's stock worth $1,277,000 after purchasing an additional 35,073 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $2,463,000. Madison Investment Advisors LLC purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $979,000. Finally, Sei Investments Co. boosted its holdings in shares of Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after acquiring an additional 20,525 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.